Tamir Biotechnology, Inc.
12625 High Bluff Dr.
Suite 113
San Diego, CA 92130
(732) 823-1003

Tamir's Lead Product Candidate, TMR004, has the potential to be a world class treatment against DNA viruses

  • A targeted RNAse inhibiting protein synthesis
  • Broad anti-viral potency; proven safety profile
  • Prior Phase III drug with endpoint in oncology
  • Leverage extensive existing safety profile with FDA

Anti-Viral Activity

  • Human Papilloma Virus (HPV)
  • Orthomyxoviruses (Influenza)
  • Middle East Respiratory Syndrome (MERS-CoV)
  • Hepatitis C Virus (HCV)
  • Cytomegalovirus (CMV)
  • Paramyxoviruses (Measles)
  • Rhabdoviruses (Rabies)


Tamir Biotechnology, Inc., is a growth-phase antiviral therapeutics company engaged in the discovery and development of a new class of prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions. Tamir's first target is the human papilloma virus (HPV), the worldwide leading cause of genital warts.

The company has successfully initiated its clinical activity in HPV along with securing independent, third-party validation of anti-viral properties for its leading candidates listed above.

Beyond HPV, Tamir has documented considerable pre-clinical anti-viral activity for the following indications: